Search This Blog

Tuesday, November 5, 2019

Antares Pharma up 6% premarket on Q3 beat

Antares Pharma (NASDAQ:ATRS) Q3 results:
Revenue: $24.7M (+113%) driven by Xyosted (sales of $7.0M) demand.
Net income: $1.0M (+182%); EPS: $0.01 (+200%).
2019 guidance: Revenue: $115M – 120M from $100M – 110M.
Previously: Antares Pharma EPS beats by $0.03, beats on revenue (Nov. 5)
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)